Funding news · Nov 17, 2026
ODAIA Raises $15M Series C+ Led by Monograph Capital for Pharma Commercial Intelligence
ODAIA Closes $15M Series C+
ODAIA, a Toronto-based AI company delivering predictive commercial intelligence for the pharmaceutical industry, has raised a $15 million Series C+ round led by Monograph Capital. The round was announced on November 17, 2026.
What ODAIA Does
ODAIA's platform unifies prescribing data, field sales activity, and digital engagement into a single view of each healthcare professional. It predicts patient journeys and surfaces missed prescription opportunities so brand, marketing, and field teams can coordinate HCP engagement from one brand strategy.
Founded in 2018 out of the University of Toronto, ODAIA serves leading biopharmaceutical companies — including four of the top 15 global organizations — through products including Brand Strategy Studio, Field Intelligence, and Marketing Intelligence.
The Round
- Round type: Series C+
- Amount: $15,000,000 USD
- Date: November 17, 2026
- Lead investor: Monograph Capital
Participating Investors
- Monograph Capital (lead)
- BDC Capital
- Wittington Ventures
- Innospark Ventures
- Flint Capital
- Threshold Ventures
- Graphite Ventures
- PHM
Why It Matters for Acquirers
ODAIA operates in a specialized niche — commercial intelligence for pharmaceutical brands — where data unification across prescribing, field sales, and digital engagement is a persistent operational challenge. The company's stated customer base includes four of the top 15 global biopharmaceutical organizations, which points to enterprise-grade deployments and validation within a demanding buyer segment.
The Series C+ structure, led by Monograph Capital with participation from a mix of Canadian and international investors including BDC Capital, Wittington Ventures, Innospark Ventures, Flint Capital, Threshold Ventures, Graphite Ventures, and PHM, suggests continued institutional support as the company scales its commercial footprint.
Company Snapshot
- Company: ODAIA
- Domain: odaia.ai
- Stage: Series C+
- Founded: 2018, out of the University of Toronto
- Focus: Predictive commercial intelligence for pharmaceuticals
- Products: Brand Strategy Studio, Field Intelligence, Marketing Intelligence
Outlook
With $15 million in new Series C+ funding led by Monograph Capital, ODAIA is positioned to continue building out its platform for pharmaceutical commercial teams. For acquisition-oriented observers, the company's enterprise relationships with leading biopharmaceutical organizations and its unified view of healthcare professional engagement are the central facts to watch.